ARTICLE | Clinical News

BioChaperone insulin combo: Preliminary Phase I/II data

March 3, 2014 8:00 AM UTC

Preliminary data from a double-blind, crossover, German Phase I/II trial in 20 Type I diabetics showed that 0.8 IU/kg BioChaperone insulin combo had a 30% faster onset of action, defined as time to >=5% reduction in glucose from baseline, vs. 0.8 IU/kg Humalog Mix insulin lispro/insulin lispro protamine. BioChaperone insulin combo comprises a version of Lantus insulin glargine that uses Adocia's BioChaperone polymer technology in combination with Humalog insulin lispro. BioChaperone insulin combo had a minimum duration of action, defined by blood glucose reaching >118 mg/dL, of >30 hours. BioChaperone insulin combo was well tolerated. Adocia plans to publish data "in a few weeks" and present complete data at a conference this year. ...